"All or nothing" push on ATMP abandoned by European Parliament
This article was originally published in Clinica
Miroslav Mikolasik, rapporteur at the European Parliament for the European Commission's proposed Advanced Therapy Medicinal Products Regulation, has terminated discussions between the European Commission, the European Parliament and the European Council aimed at reaching agreement on the text in a first reading.
You may also be interested in...
Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.